

Table 1: Summary of Included Studies

Body region affected by psoriasis	Author, year	Study	Quality of life scale	Quality of life value
Scalp/head	Andreassi, 2003	Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients	Modified Finlay–Kahn questionnaire (modified DLQI)	
	Augustin, 2018	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients	DLQI	8·0 ± 6·6
	Bahraini, 2018	Turmeric tonic as a treatment in scalp psoriasis: A randomized placebo-control clinical trial	DLQI	4

	Callis-Duffin, 2021	Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry	DLQI	8.96 (8.88–9.04)
	Egeberg, 2020	Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort	DLQI	4.7 ± 5.2
	Gual, 2016	Topical treatment for scalp psoriasis: Comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone emulsion versus calcipotriol/betamethasone gel in daily clinical practice	DLQI	8.45
	Imafuku, 2021	Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study	DLQI	7 (3-12) (median and range)
	Khobzey, 2017	Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice	DLQI	20.6

	Ohata, 2019	Fingernail Involvement is a Bigger Burden Than Face and Scalp Involvement in Patients With Psoriasis	DLQI	4.9 ± 4.9
	Radtke, 2019	Real-world experience with apremilast: Analysis of 250 patients from the APPRECIATE study with psoriasis in difficult-to-treat areas	DLQI	14 ± 7.5
	Rencz, 2014	Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity	EQ-5D	0.64 (0.29)
	Thaci, 2015	Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study	DLQI	14.1 ± 7.5
	Van Voorhees, 2020	Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study	DLQI	12.6
	Vaughn, 2019	Impact of scalp psoriasis on quality of life measurements at baseline and following treatment with ixekizumab	DLQI	12.7

	Zhou, 2018	Efficacy assessment of UVA1 and narrowband UVB for treatment of scalp psoriasis	DLQI	20.6
Neck/décoll eté	Augustin, 2018	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients	DLQI	8.9 ± 6.9
	Heredi, 2014	Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary	EQ-5D	0.48 ± 0.34
			DLQI	14.28 ± 5.95
	Jung, 2018	The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study	DLQI	16.0 ± 7.5
Facial	Augustin, 2018	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients	DLQI	8.2 ± 6.6
	Egeberg, 2020	Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort	DLQI	5.6 ± 5.5

	Heredi, 2014	Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary	EQ-5D	0.57 ± 0.37
			DLQI	11.2 ± 7.38
	Jung, 2018	The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study	DLQI	14.4 ± 8.2
	Ohata, 2019	Fingernail Involvement is a Bigger Burden Than Face and Scalp Involvement in Patients With Psoriasis	DLQI	5.5 ± 5.5
	Passos, 2019	Facial involvement and the severity of psoriasis	DLQI	7.5
	Paul, 2017	Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials	DLQI	12.9 ± 7.2

	Sharifah Rosniza Syed Nong Chek, 2016	Clinical characteristics of patients with facial psoriasis in Malaysia	DLQI	9.96
	Sojevic Timotijevic, 2013	Identification of psoriatic patients at risk of high quality of life impairment	DLQI	11.5
			PDI	15.1
	Zaghloul, 2004	Objective Assessment of Compliance With Psoriasis Treatment	DLQI	23.8 ± 3.3
Nails	Augustin, 2018	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients	DLQI	8.2 ± 6.7
	Callis-Duffin, 2021	Characterization of Patients withPsoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry	DLQI	9.39 (9.30– 9.47)

	Egeberg, 2020	Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort	DLQI	5.6 ± 5.2
	Heredi, 2014	Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary	EQ-5D	0.60 ± 0.35
			DLQI	9.61 ± 7.29
	Imafuku, 2021	Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study	DLQI (median and range)	
			Fingernail	
			Toenail	7 (3-12)
				7 (4-13)

	Khobzey, 2017	Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice	DLQI	20.2
	Klaassen, 2014	Nail Psoriasis, the unknown burden of disease	DLQI	4.9 ± 5.0
			NPQ10	9.9 ± 14.0
	Kokolakis, 2020	Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy	DLQI	12.7±7.7
	Kyriakou, 2014	Quality of life and severity of skin and nail involvement in patients with plaque psoriasis	DLQI (mean and standard deviation)	4.44 ± 2.89
			DLQI (median and range)	5.0 (1.0-12.0)



			NPQ10 (mean and s.d.)	16.38 ± 8.00
			NPQ10 (median and range)	17.5 (5.0-30.0)
	Lanna, 2020	Apremilast as a target therapy for nail psoriasis: a real-life observational study proving its efficacy in restoring the nail unit	DLQI	19.3 ± 9.2
	Ghajarzadeh, 2011	Depression and quality of life in psoriasis and psoriatic arthritis patients	DLQI	13.3 ± 10.01
			SF-36	68.4 ± 24.2
	Luger, 2009	Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis	DLQI	13.59
			EQ-5D utility	0.65

	Moradi, 2014	A comaprative cross-sectional study on health-related quality of life in psoriasis from Hungary and Iran	EQ-5D	0.47±0.4
	Ohata, 2019	Fingernail Involvement is a Bigger Burden Than Face and Scalp Involvement in Patients With Psoriasis	DLQI (mean and s.d.)	4.8 ± 4.5
	Ortonne, 2009	Development and validation of nail psoriasis quality of life scale (NPQ10)		
		Fingernails		
			DLQI	4.99
			NPQ10	10.4
		Toenails		
				6.19
			DLQI	12.9
			NPQ10	
		Fingernails and toenails		

			DLQI	9.02
			NPQ10	18.8
	Peruzzo, 2017	Nail psoriasis treated with pulsed dye laser	DLQI (median and range)	2.5 (1.0 - 11.5)
	Poulin, 2013	Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH	DLQI	12 ± 7.11
	Radtke, 2019	Real-world experience with apremilast: Analysis of 250 patients from the APPRECIATE study with psoriasis in difficult-to-treat areas	DLQI	15.7 ± 5.7
	Reich, 2010	Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial	DLQI	12.9 ± 7.2
	Reich, 2018	Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial	DLQI	12.9

	Rencz, 2014	Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity	EQ-5D	0.63 ± 0.31
	Shear, 2016	Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice	DLQI	12.3
	Sojevic Timotijevic, 2013	Identification of psoriatic patients at risk of high quality of life impairment	DLQI	12.8
			PDI	15
	Thaci, 2015	Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study	DLQI	14.4 ± 7.5
	Tsentemidou, 2017	Prevalence of onychomycosis among patients with nail psoriasis who are not receiving immunosuppressive agents: Results of a pilot study	DLQI	10.17 (7.46, 12.89)
	Masatoshi, 2010	Improvement of quality of life and clinical usefulness of cyclosporin administration in patients with nail psoriasis	PDI	15

Hands	Augustin, 2018	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients	DLQI	9.0 ± 6.8
	Heredi, 2014	Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary	EQ-5D	0.61 ± 0.35
			DLQI	9.53 ± 7.27
	Jung, 2018	The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study	DLQI	14.2 ± 7.7
	Imafuku, 2021	Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study	DLQI Median (Q1–Q3)	7 (3–12)

Genital	Augustin, 2018	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients	DLQI:	
			Genitals	9.7 ± 7.2
			Groin	9.4 ± 7.0
			Anal	8.8 ± 6.7
	Da Silva, 2019	Disease burden and patient needs and benefits in anogenital psoriasis: developmental specificities for person-centred healthcare of emerging adults and adults	DLQI	9.48
	Da Silva, 2020	Sex-related impairment and patient needs/ benefits in anogenital psoriasis:  Difficult-to- communicate topics and their impact on patient-centred care	DLQI	8.92
	Egeberg, 2020	Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort	DLQI	5.9 ± 5.6

Imafuku, 2021	Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study	DLQI (median and range)	6 (3-8)
Larsabal, 2018	GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis	DLQI (median, range)	7 (0-28)
Martinez-Ortega, 2019	Quality of life, anxiety and depressive symptoms in patients with psoriasis: A case-control study	DLQI	13.9 ± 7.2
Meeuwis, 2011	Quality of life and sexual health in patients with genital psoriasis	DLQI	8.5 ± 6.5
Ryan, 2013	Genital psoriasis is associated with significant impairment in quality of life and sexual functioning	DLQI (median, range)	4 (0-26) 3 (0-21)
De Belilovsky, 2018	Effects of a topical ointment on responses to treatments used for common genital diseases and on quality of life	DLQI	9.75

Upper limb	Augustin, 2018	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients	DLQI: <ul style="list-style-type: none"><li>- Axilla 10·4 ± 7·3</li><li>- Arms 7·9 ± 6·5</li></ul>
	Imafuku, 2021	Utility of the Dermatology Life Quality Index at initiation or switchingof biologics in real-life Japanese patients with plaque psoriasis: Resultsfrom the ProLOGUE study	DLQI (median and range) 7 (4-12)
Lower limb	Jung, 2018	The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study	DLQI: <ul style="list-style-type: none"><li>- Shoul- 15.2 ± 7.8</li><li>der 13.2 ± 7.8</li><li>- Arm</li></ul>
	Imafuku, 2021	Utility of the Dermatology Life Quality Index at initiation or switchingof biologics in real-life Japanese patients with plaque psoriasis: Resultsfrom the ProLOGUE study	DLQI (median and range): 7 (3-12) lower leg



	Jung, 2018	The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study	DLQI:  - Leg  - Foot	12.4 ± 7.7  14.7 ± 7.6
Sole	Egeberg, 2020	Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort	DLQI	5.7 ± 5.9
	Pettey, 2003	Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: Implications for clinical practice	SF-36  PDS	6.2  16.9
	Sojevic Timotijevic, 2013	Identification of psoriatic patients at risk of high quality of life impairment	DLQI  PDI	14.9  18.2
Palm	Egeberg, 2020	Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort	DLQI	5.7 ± 5.8

	Petty, 2003	Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: Implications for clinical practice	SF-36  PDS	19.8  52.7
	Sojevic  Timotijevic, 2013	Identification of psoriatic patients at risk of high quality of life impairment	DLQI  PDI	11.9  15.6
Palmoplantar	Bissonnette, 2018	Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study	DLQI:  - Group A  - Group B	10.4 ± 6.3  8.6 ± 6.7
	Callis Duffin, 2021	Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry	DLQI	10.25  (10.17–  10.32)

	Chung, 2014	Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis	DLQI (median and range)	4 (1-9)
			EQ-5D (median and range)	0.83 (0.75-1.0)
	Gottlieb, 2017	Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial	DLQI	13.33
	Heredi, 2014	Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary	EQ-5D	0.36 ± 0.39
			DLQI	11.42 ± 6.82
	Moradi, 2014	A comparative cross-sectional study on health-related quality of life in psoriasis from Hungary and Iran	EQ-5D	0.36±0.3

	Rencz, 2014	Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity	EQ-5D	0.48 ± 0.31
	Richetta, 2012	Safety and efficacy of Adalimumab in the treatment of moderate to severe palmo-plantar psoriasis: an open label study	DLQI	12.27
Inverse	Cohen, 2016	Shedding Light on the "Hidden Psoriasis": A Pilot Study of the Inverse Psoriasis Burden of Disease (IPBOD) Questionnaire	DLQI	8.5
			IPBOD	4.9
	Rencz, 2014	Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity	EQ-5D	0.61 ± 0.33
Chest/abdomen	Jung, 2018	The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study	DLQI	13.5 ± 7.6
Back/buttocks	Jung, 2018	The association of socioeconomic and clinical characteristics with health-related quality of life in patients with psoriasis: a cross-sectional study	DLQI	13.5 ± 7.7

